Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5146 Target Snapshot

Breakpoint cluster region protein · SINGLE PROTEIN · Homo sapiens

269Compounds
23Assays
17Approved Drugs
267.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P11274. Use UniProt P11274 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P11274 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Breakpoint cluster region protein as ChEMBL target CHEMBL5146, mapped to UniProt P11274. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Breakpoint cluster region protein
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5146
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11274
Breakpoint cluster region protein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Breakpoint cluster region protein is the right protein anchor across sources, using UniProt P11274 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBreakpoint cluster region protein
UniProt AccessionP11274
Component TypeProtein
Sequence Length1271 aa

Breakpoint cluster region protein

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Breakpoint cluster region protein, mapped to UniProt P11274. Sequence length is 1271 aa.

Mapped IDP11274
Review nameBreakpoint cluster region protein
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

17
Approved
6
Phase III
16
Phase II
13
Phase I
Assay Mix

Activity Type Distribution

IC5023.0
KD244.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL400402 9.0 Kd 1.0 Preclinical
CHEMBL288441 8.52 Kd 3.0 Approved
CHEMBL3545085 8.52 Kd 3.0 Preclinical
CHEMBL402548 8.3 Kd 5.0 Clinical
CHEMBL5416410 8.3 Kd 5.0 Approved
CHEMBL941 8.15 Kd 7.0 Approved
CHEMBL3600873 7.96 Kd 11.0 Preclinical
CHEMBL3688339 7.85 Kd 14.0 Preclinical
CHEMBL206834 7.82 Kd 15.0 Clinical
CHEMBL217092 7.8 Kd 16.0 Clinical
Distribution

pChEMBL Value Distribution

3
5.0
14
5.5
16
6.0
9
6.5
6
7.0
4
7.5
3
8.0
2
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOVORAFENIB
CHEMBL3348923
Approved 2024
TIVOZANIB
CHEMBL1289494
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
CABOZANTINIB
CHEMBL2105717
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

23
Total Assays
60
Tested Compounds
1
Assay Types
Binding — 23 assays, 60 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 18 0
single protein format 3 5 6.3
assay format 1 0
subcellular format 1 55 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine